Journal of Hematology & Oncology

Papers
(The H4-Index of Journal of Hematology & Oncology is 91. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans722
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024688
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases686
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma661
Recent advances in targeting protein degradation for tumor immunotherapy651
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and577
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency443
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects421
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening410
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018380
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies366
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ354
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China343
Cancer vaccines: current status and future directions330
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy300
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2297
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis293
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration266
Landscape of biallelic DNMT3A mutant myeloid neoplasms263
Personalized nanovaccines for treating solid cancer metastases241
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients226
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation221
HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors218
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)218
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p213
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression208
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts206
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma201
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis198
Ferroptosis: principles and significance in health and disease189
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1189
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway189
Recent advances in therapeutic strategies for non-small cell lung cancer184
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis182
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global 179
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?177
Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer172
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology168
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation165
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis163
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study160
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs152
Small RNA modifications: regulatory molecules and potential applications149
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy149
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia146
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients146
3D chromatin architecture and transcription regulation in cancer141
Recent advances in targeted strategies for triple-negative breast cancer141
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model138
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages138
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response138
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study137
The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials137
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer136
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis135
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment131
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study130
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation129
A single-cell and spatially resolved atlas of human osteosarcomas129
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure129
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies128
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth128
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma122
Target neutrophil heterogeneity and plasticity in cancer121
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia120
Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting119
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry116
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting115
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives115
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype115
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts114
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects114
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting112
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia112
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers112
Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer111
The functional and clinical roles of liquid biopsy in patient-derived models106
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting105
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies104
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia104
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia103
Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee97
Echinomycin as a promising therapeutic agent against KSHV-related malignancies96
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II 94
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting94
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function93
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting93
Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies91
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis91
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial91
Worked to the bone: antibody-based conditioning as the future of transplant biology91
0.080785989761353